340B Outlook For 2024: Change. Change. And More Change.

January 12, 2024340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, News Updates, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

What we’ve learned. What it means for your 340B program. Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to more than $500 million in savings generated for the hospitals and health systems we serve. In spite of the drug manufacturer restrictions that have devastated many hospitals’ programs, every … Read More

Leveraging Partnerships With Drug Manufacturers To Overcome 340B Restrictions On Specialty Drugs

December 11, 2023340B, 340B ESP, Bedside Prescription Delivery, Drug Manufacturer Restrictions, Medicare, Meds To Beds, PBM, Specialty Drugs, Specialty Drugs, Specialty Pharmacy

It’s no secret that the 340B Drug Pricing Program has been a lifeline for eligible health systems, enabling them to fill-in the massive revenue gaps inherent to the non-profit-hospital business model (and, in the process, support their mission of providing quality care to our nation’s most vulnerable patients) through access to discounted prescription refills. At … Read More

Your Hospital’s 340B Contract Pharmacy Network Is Not What It Should Be.

November 15, 2023340B, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Patient Eligibility, PBM, Prescription Discounts, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs, Uncategorized

Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when ProxsysRx launched its 340B Support Services division, we’ve managed the 340B programs of 18 health systems. Altogether, we’ve generated more than $500 million in 340B Savings and Revenue for those health systems — $98M in the first 10 months … Read More

ProxsysRx’s Meds To Beds Program Makes Immediate Impact Upon Launch At TMH

September 26, 2023340B, Bedside Prescription Delivery, Meds To Beds, Prescription Discounts, Retail / Outpatient Pharmacy, Specialty Pharmacy

To date, we’ve published a dozen posts either detailing, or mentioning-in-passing, the clinical and financial benefits a well-run Meds To Beds program offers hospitals and the patients they serve. Which is why we thought it was time to report some of the personal benefits our program delivers — with a handful of stories we’ve heard … Read More

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

August 22, 2023340B, 340B ESP, Bedside Prescription Delivery, Compliance, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Prescription Discounts, Requirements, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

Why a Specialty Pharmacy? (Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. According to a report by The American Hospital Association, the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase … Read More

How ProxsysRx Quadrupled One 340B Entity’s Savings & Revenue In A Single Quarter

June 21, 2023340B, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Retail / Outpatient Pharmacy, Specialty Pharmacy

In late 2022, ProxsysRx’s team initiated 340B Program-Management support for a 198-bed, full-service, community and regional non-profit medical center located in the Northeast. After weeks of laying all the necessary groundwork to manage its 340B program, we began actively submitting eligible prescriptions this past January. By the end of Q1, the hospital’s 2023 340B savings … Read More

The 2023 Guide To Implementing An Effective 340B Program

May 24, 2023340B, 340B ESP, Bedside Prescription Delivery, Compliance, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, PBM, Requirements, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

The 340B-program landscape has changed dramatically. For the 340B program’s first 28 years after its 1992 inception, the basic list of Best Practices for eligible entities (the 340B basics, if you will) remained largely unchanged — aside from the dramatically-increased importance of using specialized software. But since the June, 2020 introduction of 340B ESP — … Read More

Why 340B Hospitals Should Now Build Their Own Specialty Pharmacies

May 3, 2023340B, 340B ESP, Covered Entities, Drug Manufacturer Restrictions, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

340B ESP and drug manufacturer restrictions are only part of the reason As we noted in a previous post, for 340B-eligible hospitals dealing with increasingly squeezed bottom lines, an in-house specialty pharmacy offers enormous savings and revenue potential. Some covered entities generate as much as 600% in specialty pharmacy revenue from 340B drugs as they … Read More

Brick Walls: Dealing With 340B Manufacturer Restrictions.

February 23, 2023340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, PBM, Requirements, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

A ProxsysRx Team Member Speaks Out. I joined ProxsysRx in early 2021, and I’ve been devoted to 340B program management full-time since early 2022. I’m no stranger to heavily regulated programs. Nearly my whole professional career has been in some aspect of public health — preclinical, clinical and now post-clinical. I’m currently fully devoted to … Read More

Seven Steps For Overcoming 340B ESP and Other Manufacturer Restrictions on 340B Pricing

December 20, 2022340B, 340B ESP, Contract Pharmacy, Covered Entities, Requirements, Specialty Drugs, Specialty Pharmacy

ProxsysRx’s process for recovering lost 340B savings and revenue As we’ve noted in multiple earlier blog posts, 340B ESP is nothing short of a blatant, lawless tactic used by scores of drug manufacturers to disallow the discounts they are legally obligated to offer eligible entities. At the same time, a number of additional manufacturers are … Read More